Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · LeMaitre Vascular (LMAT)

LeMaitre Q3 sales rise 16% to $54.8 million and full-year guidance is raised

Positive Impact 4 of 5 guidance Written later

LeMaitre Vascular reported preliminary, unaudited results for the quarter ended September 30, 2024, with net sales of $54.8 million, up 16% from a year earlier, and diluted earnings per share of $0.49, up from $0.33. The company also raised its full-year 2024 guidance, which for sales is $219.0 million to $221.0 million and for EPS is $1.91 to $1.96, giving shareholders a higher outlook for growth and profit.

Key points

  • Q3 2024 net sales were $54.8 million, up from $47.4 million in Q3 2023.
  • Q3 operating income was $13.1 million, up from $9.2 million, and diluted EPS was $0.49 versus $0.33.
  • Full-year 2024 sales guidance is $219.0 million to $221.0 million, and EPS guidance is $1.91 to $1.96.
  • The Board approved a $0.16 per share quarterly dividend, payable December 5, 2024, to holders of record on November 21, 2024.

The filing

CompanyLeMaitre Vascular (LMAT)
Form8-K, current report
Filed with the SECOct 31, 2024, 4:02 PM ET
Accession number0001437749-24-032784

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 31, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.